Automation Workflow for Identifying Novel Biological Targets

Manual hypothesis generation is limited by researcher bandwidth and known literature. This multi-agent workflow analyzes multi-omics datasets, protein interaction networks, and scientific literature at a scale impossible for human teams, systematically surfacing novel targets beyond established disease genes. This directly expands the target universe, creating opportunities for breakthrough therapies in areas with high unmet need.

Traditional target identification involves sequential, manual analysis of fragmented data sources, followed by lengthy literature reviews and committee discussions. An orchestrated AI workflow (using LangGraph or CrewAI) runs parallel analyses, fuses evidence in real-time, and generates ranked, hypothesis-ready reports. This compresses the initial discovery phase, allowing portfolio teams to initiate projects 6-9 months faster.

Pursuing poorly validated targets wastes millions on failed preclinical work. This workflow de-risks investment by generating targets with integrated genetic, omics, and mechanistic evidence, plus proposed validation plans. By front-loading rigorous, automated due diligence, organizations avoid costly dead-ends and improve the probability of technical success (PTS) for new programs, protecting R&D capital.

Target selection is often influenced by internal bias or competitor activity. This workflow creates an auditable, data-first pipeline by logging all evidence sources, scoring logic, and decision rationales into a knowledge graph (e.g., Neo4j). This provides governance teams with a clear, defendable basis for portfolio decisions and strengthens regulatory submissions by demonstrating a systematic approach to target identification.

Manual processes don't scale with data growth. A production-grade workflow, built on cloud-native orchestration, can continuously ingest new omics data, clinical trial results, and patent filings. It automatically re-evaluates and re-ranks targets, turning discovery from a project-based activity into a perpetual, operational capability that keeps the pipeline fresh and responsive to emerging science.

A hypothesis is useless without a clear path to test it. The workflow's final output isn't just a target list; it's a structured validation plan. Specialized agents propose CRISPR knockout studies, animal models, and available chemical probes, and can even draft experimental protocols. This accelerates the handoff to biology teams, shrinking the time from AI-generated insight to lab-based confirmation.

This agent orchestrates the ingestion and normalization of genomics, transcriptomics, and proteomics data from internal repositories (e.g., DNAnexus, Seven Bridges) and public sources (e.g., TCGA, GTEx). It applies statistical and ML pipelines for differential expression, pathway enrichment, and network propagation to surface candidate genes with strong disease association. The agent's output is a structured, ranked list of potential targets with supporting genetic evidence, replacing months of manual bioinformatics analysis.

A continuously running LLM-powered agent scans PubMed, preprint servers, and internal research reports. It extracts and links key entities (genes, proteins, diseases, mechanisms) to populate a dynamic knowledge graph in Neo4j or AWS Neptune. This creates a living evidence base that connects novel candidate targets to published biology, competitive intelligence, and mechanistic hypotheses, ensuring project teams operate on the latest science without manual literature review.

This component is a rule-based agent that scores candidate targets for pharmacological feasibility. It queries structured databases like ChEMBL, PDB, and commercial druggability platforms to assess factors like: binding pocket geometry, known ligandability, tissue expression, and safety profile (genetic knockout phenotypes). Targets are scored and filtered, preventing investment in biologically compelling but 'undruggable' proteins.

This reasoning agent synthesizes outputs from the omics, literature, and druggability agents to formulate specific, testable biological hypotheses (e.g., 'Inhibiting protein X will reduce tumor growth in Y context via Z pathway'). It then drafts a proposed experimental validation plan, suggesting key in vitro and in vivo assays, required reagents (e.g., CRISPR kits, antibodies), and potential CRO partners. This bridges AI discovery to lab operations.

A centralized dashboard (built with Streamlit or Retool) serves as the system's UI and governance checkpoint. It displays the ranked target pipeline, supporting evidence, and validation plans. Integrated approval workflows allow project teams, biology leads, and portfolio managers to review, prioritize, and commit resources to new targets. All decisions, rationale, and data lineage are logged for auditability, connecting the automated workflow to enterprise R&D governance.

This is the critical data plumbing layer. It uses secure APIs and event-driven orchestration (via Apache Airflow or Prefect) to connect the AI workflow to downstream enterprise systems. When a target is approved, it automatically creates project workspaces in electronic lab notebooks (IDBS ELN, Benchling), triggers material requests in LIMS, and updates portfolio trackers in systems like Veeva R&D. This ensures the AI-generated hypothesis flows seamlessly into the operational R&D value chain.

The primary business buyer and scientific sponsor. They define the biological hypotheses, disease areas, and success criteria (e.g., 'identify 3 novel, genetically-validated oncology targets per quarter'). They own the pipeline impact and ROI case, focusing on expanding the target universe for first-in-class medicines and diversifying the portfolio. They champion the budget and ensure the workflow outputs integrate into existing project initiation governance.

The technical buyer and workflow architect. They specify the required data sources (multi-omics repositories, protein interaction networks, literature corpora), define the analytical pipelines (pathway analysis, network propagation), and validate the biological plausibility of AI-generated hypotheses. They work with the solutions architect to translate scientific requirements into agent specifications, data connectors, and validation checkpoints within the orchestration layer (e.g., LangGraph).

The build and delivery team responsible for the core implementation. They develop and containerize the specialized AI agents for literature mining, omics integration, and network analysis. They build the orchestration logic (using frameworks like LangChain or CrewAI) to sequence agents, manage state, and route exceptions. This team also provisions the scalable cloud infrastructure (AWS/GCP/Azure) for data processing and model serving, ensuring the system meets performance SLAs for hypothesis generation cycles.

The compliance and enablement stakeholders. They govern access to sensitive internal omics data, genomic databases, and proprietary research. They mandate the security architecture for the workflow, requiring features like data encryption in transit/at rest, audit trails for all AI-generated hypotheses, and strict access controls. Their sign-off is required for production deployment, and they often drive the implementation of federated learning patterns if external consortium data is used.

The downstream consumer and critical reviewer. This role assesses the technical feasibility of validating AI-proposed targets. They define the requirements for the workflow's output package, which must include not just a target protein but a proposed experimental validation plan (e.g., CRISPR knockout, phenotypic assay). They provide feedback that retrains the AI models, creating a closed-loop system where wet-lab results improve future target prioritization.

The integration and orchestration expert who translates stakeholder needs into a production-grade automation blueprint. This role designs the end-to-end workflow architecture, selecting and connecting the agent frameworks, cloud services, and legacy system APIs (e.g., ELNs, internal knowledge graphs). They own the technical roadmap, exception handling design, and observability layer (logging, monitoring, dashboards) to ensure the system is reliable, debuggable, and delivers measurable ROI.